AFMD - Affimed's Novel Immune Engineering Approach In Oncology
- In an increasingly saturated landscape of immune oncology companies, Affimed presents a new solution through innate NK cell therapies designed to fight relapsed cancers.
- Affimed’s core technology has garnered corporate interest in the sector, leading to immune oncology partnerships being established with Merck, Genentech, and Roivant.
- With a small core of drug candidates driving their focused pipeline, Affimed has good control over burn rate without needing to fund many early stage trials.
- Recent readouts have caused a surge in share price diminishing potential value, but the growth thesis of this company shows great potential when looking at the bigger picture.
For further details see:
Affimed's Novel Immune Engineering Approach In Oncology